Israeli drugmaker Teva says that patient recruitment has begun in a landmark study that will evaluate whether its drug Agilect/Azilect (rasagiline) can attenuate Parkinson's disease.
The ADAGIO study is expected to enroll up to 1,100 patients across 135 centers in 14 countries and is the first that will investigate whether a drug can slow the progression of the neurodegenerative disorder.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze